Frontiers in Oncology (Sep 2021)

The Role of Non-Coding RNAs in Breast Cancer Drug Resistance

  • Jin-hai Tian,
  • Jin-hai Tian,
  • Shi-hai Liu,
  • Chuan-yang Yu,
  • Chuan-yang Yu,
  • Li-gang Wu,
  • Li-bin Wang,
  • Li-bin Wang

DOI
https://doi.org/10.3389/fonc.2021.702082
Journal volume & issue
Vol. 11

Abstract

Read online

Breast cancer (BC) is one of the commonly occurring malignancies in females worldwide. Despite significant advances in therapeutics, the mortality and morbidity of BC still lead to low survival and poor prognosis due to the drug resistance. There are certain chemotherapeutic, endocrine, and target medicines often used for BC patients, including anthracyclines, taxanes, docetaxel, cisplatin, and fluorouracil. The drug resistance mechanisms of these medicines are complicated and have not been fully elucidated. It was reported that non-coding RNAs (ncRNAs), such as micro RNAs (miRNA), long-chain non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) performed key roles in regulating tumor development and mediating therapy resistance. However, the mechanism of these ncRNAs in BC chemotherapeutic, endocrine, and targeted drug resistance was different. This review aims to reveal the mechanism and potential functions of ncRNAs in BC drug resistance and to highlight the ncRNAs as a novel target for achieving improved treatment outcomes for BC patients.

Keywords